Ritwik Sinha
Zitiert von
Zitiert von
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who …
K Porkka, HJ Khoury, RL Paquette, Y Matloub, R Sinha, JE Cortes
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)
MJ Mauro, M Baccarani, F Cervantes, JH Lipton, Y Matloub, R Sinha, ...
Journal of Clinical Oncology 26 (15_suppl), 7009-7009, 2008
Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study
BA Rybicki, R Sinha, S Iyengar, C Gray-McGuire, RC Elston, MC Iannuzzi
Genes & Immunity 8 (5), 379-386, 2007
Predicting reactions to short-text posts
BV Srinivasan, A Natarajan, R Sinha, V Gupta, SV Revankar, B Ravindran
US Patent 9,256,826, 2016
Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP)
M Baccarani, G Rosti, G Saglio, J Cortes, R Stone, DW Niederwieser, ...
Blood 112 (11), 450, 2008
Genetic characterization and fine mapping of susceptibility loci for sarcoidosis in African Americans on chromosome 5
C Gray-McGuire, R Sinha, S Iyengar, C Millard, BA Rybicki, RC Elston, ...
Human genetics 120 (3), 420-430, 2006
Optimal time to post for maximum social engagement
BV Srinivasan, N Anandhavelu, R Sinha, S Revankar
US Patent 9,607,273, 2017
A non-parametric approach to the multi-channel attribution problem
MM Yadagiri, SK Saini, R Sinha
International conference on web information systems engineering, 338-352, 2015
Marketing channel attribution
R Sinha, SK Saini, N Anandhavelu
US Patent App. 14/508,141, 2016
Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal …
A Hochhaus, MC Müller, J Radich, S Branford, B Hanfstein, P Rousselot, ...
Blood 112 (11), 1095, 2008
Multiple testing in the genomics era: findings from Genetic Analysis Workshop 15, Group 15
LJ Martin, JG Woo, CL Avery, HS Chen, KE North, Group 15
Genetic Epidemiology 31 (S1), S124-S131, 2007
Probabilistic deduplication of anonymous web traffic
R Saha Roy, R Sinha, N Chhaya, S Saini
Proceedings of the 24th International Conference on World Wide Web, 103-104, 2015
Estimating the incremental effects of interactions for marketing attribution
R Sinha, S Saini, N Anadhavelu
2014 International Conference on Behavioral, Economic, and Socio-Cultural …, 2014
Saliency prediction for a mobile user interface
P Gupta, S Pal, S Gupta, R Sinha, A Jayagopal
US Patent 10,664,999, 2020
Summarization and communication of large data sets
R Sinha, P Kumar, A Rohith, R Kateja
US Patent 10,088,974, 2018
Saliency prediction for mobile user interfaces
P Gupta, S Gupta, A Jayagopal, S Pal, R Sinha
2018 IEEE Winter Conference on Applications of Computer Vision (WACV), 1529-1538, 2018
The affected-/discordant-sib-pair design can guarantee validity of multipoint model-free linkage analysis of incomplete pedigrees when there is marker-marker disequilibrium
C Xing, R Sinha, G Xing, Q Lu, RC Elston
The American Journal of Human Genetics 79 (2), 396-401, 2006
Joint modeling tumor burden and time to event data in oncology trials
Y Shen, A Anderson, R Sinha, Y Li
Pharmaceutical Statistics 13 (5), 286-293, 2014
Will your facebook post be engaging?
BV Srinivasan, A Natarajan, R Sinha, V Gupta, S Revankar, B Ravindran
Proceedings of the 1st workshop on User engagement optimization, 25-28, 2013
Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib …
MWN Deininger, MJ Mauro, Y Matloub, R Sinha, L Ploughman, D Liu, ...
Blood, The Journal of the American Society of Hematology 112 (11), 3236-3236, 2008
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20